Eugene Swenson

1.8k total citations · 1 hit paper
19 papers, 1.0k citations indexed

About

Eugene Swenson is a scholar working on Hepatology, Nutrition and Dietetics and Epidemiology. According to data from OpenAlex, Eugene Swenson has authored 19 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Hepatology, 8 papers in Nutrition and Dietetics and 7 papers in Epidemiology. Recurrent topics in Eugene Swenson's work include Hepatitis C virus research (10 papers), Liver Disease Diagnosis and Treatment (7 papers) and Trace Elements in Health (6 papers). Eugene Swenson is often cited by papers focused on Hepatitis C virus research (10 papers), Liver Disease Diagnosis and Treatment (7 papers) and Trace Elements in Health (6 papers). Eugene Swenson collaborates with scholars based in United States, France and Denmark. Eugene Swenson's co-authors include William Curatolo, William B. Milisen, Fiona McPhee, Eric Hughes, Charles Landis, John M. Vierling, Stephanie Noviello, Eugene R. Schiff, Fred Poordad and Rong Yang and has published in prestigious journals such as Hepatology, Advanced Drug Delivery Reviews and Journal of Hepatology.

In The Last Decade

Eugene Swenson

17 papers receiving 994 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence

2016 331 citations Fred Poordad, Eugene R. Schiff et al. Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eugene Swenson United States	10	452	429	332	178	121	19	1.0k
Marina H. de Jager Netherlands	17	186 0.4×	120 0.3×	74 0.2×	277 1.6×	437 3.6×	26	1.2k
J. J. Keating Ireland	16	168 0.4×	202 0.5×	32 0.1×	100 0.6×	61 0.5×	35	701
Bojan Stanimirov Serbia	13	28 0.1×	79 0.2×	124 0.4×	218 1.2×	188 1.6×	31	597
Johannes B. van Bree Netherlands	11	52 0.1×	54 0.1×	316 1.0×	141 0.8×	203 1.7×	13	1.2k
A K Azad Khan United Kingdom	5	42 0.1×	373 0.9×	54 0.2×	73 0.4×	125 1.0×	10	949
Esther G. van de Kerkhof Netherlands	6	89 0.2×	68 0.2×	45 0.1×	128 0.7×	224 1.9×	8	551
Sagar Trivedi India	14	76 0.2×	118 0.3×	51 0.2×	45 0.3×	26 0.2×	50	524
A. Bremmelgaard Denmark	13	167 0.4×	204 0.5×	39 0.1×	136 0.8×	608 5.0×	24	1.0k
E. Musch Germany	14	61 0.1×	130 0.3×	24 0.1×	127 0.7×	152 1.3×	44	623
José Vázquez‐Tato Spain	6	45 0.1×	107 0.2×	31 0.1×	148 0.8×	254 2.1×	8	535

Countries citing papers authored by Eugene Swenson

Since Specialization

Citations

This map shows the geographic impact of Eugene Swenson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eugene Swenson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eugene Swenson more than expected).

Fields of papers citing papers by Eugene Swenson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eugene Swenson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eugene Swenson. The network helps show where Eugene Swenson may publish in the future.

Co-authorship network of co-authors of Eugene Swenson

This figure shows the co-authorship network connecting the top 25 collaborators of Eugene Swenson. A scholar is included among the top collaborators of Eugene Swenson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eugene Swenson. Eugene Swenson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Munk, Ditte Emilie, Eugene Swenson, Mikkel Holm Vendelbo, et al.. (2023). Effects of tetrathiomolybdate on copper metabolism in healthy volunteers and in patients with Wilson disease. Journal of Hepatology. 80(4). 586–595. 31 indexed citations

Munk, Ditte Emilie, Eugene Swenson, Mikkel Holm Vendelbo, et al.. (2023). Effects of tetrathiomolybdate, trientine, and penicillamine on intestinal copper uptake: a randomized placebo-controlled 64Cu PET/CT study. Journal of Hepatology. 78. S958–S959.

Munk, Ditte Emilie, Eugene Swenson, Mikkel Holm Vendelbo, et al.. (2023). Effects of trientine and penicillamine on intestinal copper uptake: A mechanistic 64Cu PET/CT study in healthy humans. Hepatology. 79(5). 1065–1074. 12 indexed citations

Liang, Tao, Linwen Zhang, Scott Moseley, et al.. (2022). Development and validation of a novel ICP-MS method to quantify different copper species in human plasma from patients with Wilson disease. Journal of Hepatology. 77. S526–S526. 2 indexed citations

Weiss, Karl Heinz, Michael L. Schilsky, Anna Członkowska, et al.. (2022). O01 Efficacy and safety of ALXN1840 versus standard of care in Wilson disease: primary results from an ongoing phase 3, randomized, controlled, rater-blinded trial. Abstracts. A1–A1. 1 indexed citations

Weiss, Karl Heinz, Michael L. Schilsky, Anna Członkowska, et al.. (2022). Efficacy and safety of ALXN1840 versus standard of care in Wilson disease: primary results from an ongoing phase 3, randomized, controlled, rater-blinded trial. Journal of Hepatology. 77. S1–S1. 4 indexed citations

Kao, Jia‐Horng, Ming‐Lung Yu, Chung‐Kang Peng, et al.. (2017). Daclatasvir/asunaprevir/beclabuvir, all‐oral, fixed‐dose combination for patients with chronic hepatitis C virus genotype 1. Journal of Gastroenterology and Hepatology. 32(12). 1998–2005. 9 indexed citations

Poordad, Fred, et al.. (2017). An HCV‐positive recipient of an HCV‐positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin. Clinical Case Reports. 5(4). 371–375. 1 indexed citations

Poordad, Fred, Eugene R. Schiff, John M. Vierling, et al.. (2016). Daclatasvir, Sofosbuvir, and Ribavirin Combination for HCV Patients with Advanced Cirrhosis or Post-transplant Recurrence: Final Results of the ALLY-1 Study: 2016 ACG Presidential Poster Award. The American Journal of Gastroenterology. 111. S346–S346.

10.

Poordad, Fred, Eugene R. Schiff, John M. Vierling, et al.. (2016). Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence. Hepatology. 63(5). 1493–1505. 331 indexed citations breakdown →

11.

Sulkowski, Mark, S. Flamm, Zeid Kayali, et al.. (2016). Short‐duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study). Liver International. 37(6). 836–842. 23 indexed citations

12.

Poordad, F., Rosanna Fontana, Eugene R. Schiff, et al.. (2016). Factors Impacting SVR12 for Patients with Advanced Cirrhosis Receiving Daclatasvir and Sofosbuvir with Ribavirin in the Ally-1 Study. Journal of Hepatology. 64(2). S768–S769. 8 indexed citations

13.

Hézode, Christophe, Robert Herring, Paul J. Pockros, et al.. (2015). P0888 : Effect of baseline factors on response to the fixed-dose combination of daclatasvir (DCV), asunaprevir (ASV) and beclabuvir (BCV), with or without ribavirin (RBV), in patients with HCV genotype 1 infection and cirrhosis. Journal of Hepatology. 62. S676–S676. 1 indexed citations

14.

Reddy, K. Rajender, Kimberly L. Beavers, Stuart C. Gordon, et al.. (2015). P0889 : Effect of baseline factors on response to the fixed-dose combination of daclatasvir (DCV), asunaprevir (ASV) and beclabuvir (BCV) in non-cirrhotic patients with HCV genotype 1 infection. Journal of Hepatology. 62. S676–S677. 3 indexed citations

15.

Poordad, Fred, Eugene R. Schiff, John M. Vierling, et al.. (2015). LO8 : Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or posttransplant recurrence: Phase 3 ALLY-1 study. Journal of Hepatology. 62. S261–S262. 69 indexed citations

16.

Swenson, Eugene, et al.. (2014). Prevention of Neonatal Hepatitis B Virus Transmission. Journal of Clinical Gastroenterology. 48(9). 765–772. 14 indexed citations

17.

Swenson, Eugene, William B. Milisen, & William Curatolo. (1994). Intestinal Permeability Enhancement: Structure-Activity and Structure-Toxicity Relationships for Nonylphenoxypolyoxyethylene Surfactant Permeability Enhancers. Pharmaceutical Research. 11(10). 1501–1504. 33 indexed citations

18.

Swenson, Eugene, William B. Milisen, & William Curatolo. (1994). Intestinal Permeability Enhancement: Efficacy, Acute Local Toxicity, and Reversibility. Pharmaceutical Research. 11(8). 1132–1142. 221 indexed citations

19.

Swenson, Eugene & William Curatolo. (1992). (C) Means to enhance penetration. Advanced Drug Delivery Reviews. 8(1). 39–92. 278 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact